Narjust Florez: Amazing discussion with the leaders that made ALK + NSCLC a treatable disease
Narjust Florez shared a post by IASLC on X, adding:
“Amazing discussion with the leaders that made ALK + NSCLC a treatable disease and many more survivors.
From developing testing to recruiting patients from across the globe.
One of my favorite podcasts.”
Quoting IASLC’s post:
“In this special Lung Cancer Considered episode, hosts Narjust Florez and StephenV Liu moderate a discussion on the seminal PROFILE-1001 trial. With guests Dr. Alice Shaw, Dr. Ben Solomon, and Dr. Ignatius Ou. Listen Now.”
Source: Narjust Florez/X and IASLC/X
Narjust Florez is the Associate Director of the Cancer Care Equity Program and a Thoracic Medical Oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer.
In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023